The global PD1-resistant head and neck cancer market is expected to reach a valuation of USD 1.54 Billion in 2023 and is projected to reach USD 5 Billion by 2033, with a CAGR of 12.5%. The growing geriatric population and rising number of initiatives by government and non-governmental organizations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer(SPOHNC) are creating a highly conducive environment for the growth of the global PD1-resistant head and neck cancer market.
The robust presence of the product pipeline and their expected launch will fuel the market growth. Some of the products in the pipeline are Tipifarnib (Farnesyltransferase Inhibitor), tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Rozlytrek (entrectinib), and Afatinib. Successful completion of trials and consequent approval is expected to drive market growth over the forecast period. In February 2021, the USA FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug which will aid in market expansion.
The increasing prevalence of PD1 Resistant Head and Neck Cancer due to several factors such as alcohol consumption, tobacco consumption, Epstein-Barr virus (EBV) infection, and human papillomavirus (HPV) infection is significantly propelling the demand for PD1 Resistant Head and Neck Cancer drugs that bolsters HNC therapeutics market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.54 Billion |
| Anticipated Forecast Value (2033) | USD 5 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 12.5% |
The PD1 Resistant Head and Neck Cancer Market were growing at a CAGR of 10.1% while valued at USD 1 Billion during the historical period. The rapidly growing pharmaceutical industry and the rising expenditure by the top market players in research and development and the availability of various pipeline drugs such as atezolizumab, Afatinib, and Ipilimumab are fuelling the market growth. Considering these factors HNC market is projected to reach USD 5 Billion with a CAGR of 12.5% during the forecast period.
Advances in biochemistry and Genomics to propel market growth
The advancements in non-surgical procedures and therapies such as immunotherapy and targeted therapy are supporting the adoption rate of PD1-resistant head and neck cancer drugs among patients across the globe. The availability of advanced diagnostic tools to diagnose various types of cancer and tumors is driving market growth.
The increasing awareness among the population regarding the availability of effective and innovative drugs to treat cancer coupled with rising healthcare expenditure is fuelling the PD1-resistant head and neck cancer market growth. The swiftly growing biopharmaceutical industry and the rising penetration of online pharmacies are the major factors that are anticipated to augment the growth of the market during the forecast period.
Moreover, several developmental strategies such as partnerships, new product launches, and adoption of the latest technologies impact the market positively and drive the industry’s growth. The growing expenditure by the top market players in research and development and the availability of various pipeline drugs such as atezolizumab, Afatinib, and Ipilimumab is also aiding in market expansion.
High rate of complications to restrain market expansion
Rising treatment costs, an increase in the adverse effects associated with the use of PD1 Resistant Head and Neck Cancerdrugs, high rate of complications, dearth of early cancer detection, and lack of awareness among patients and physicians about head and neck treatment are the major factors acting as restraints, and will further hinder the PD1 Resistant Head and Neck Cancerdrug market during the forecast period. Moreover, the dearth of proper healthcare facilities and oncology professionals across some developing and underdeveloped regions is also restricting market expansion.
North American PD1-resistant head and neck cancer market accounted for 46% market share in 2022. It is estimated to retain its dominance while exhibiting a CAGR of 11.1% during the forecast period. In this region, the US market is expected to gross a market value of USD 850 Million by end of the forecast period.
The presence of advanced healthcare infrastructure, robust product pipeline increased healthcare expenditure, favorable reimbursement policies, and improved access to advanced diagnostic devices are the major factors that drive the growth of the PD1 Resistant Head and Neck Cancer drugs market in the North American region.
In Asia Pacific, the market is projected to grow with the fastest CAGR of 11.5% with a market valuation to reach USD 425 Million by 2033. The growing geriatric population and increasing prescription of immunotherapy drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) for the treatment of various types of HNC are anticipated to drive market growth in coming years. China is expected to dominate the market in this region with a market valuation of around USD 250 Million. Moreover, the market in Japan will be fuelled with a CAGR of 11%. Additionally, the Indian market will witness a CAGR of 11.2% during the forecast period.
Currently, four targeted therapies are existing in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo, and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less dependent on chemotherapy options.
With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea, and Japan, there has been a rise in targeted therapy options. Additionally, avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of 2033, as it is currently undergoing Phase III trials in Japan, Australia, and South Korea.
Increasing demand for efficient drugs for the treatment of HNCs in emerging economies such as China and India, the growing pharmaceutical industry, and the rapidly increasing patient population are expected to fuel the growth of the market in Asia Pacific during the forecast period.
The increasing special drug designations and the high efficacy of EGFR inhibitors in the treatment of cancer indications e.g., lung cancer, colorectal cancer, and breast cancer will result in quicker approval during the clinical stages.
Thus, the robust prevalence of major cancer indications will be a significant factor driving the epidermal growth factor receptor inhibitors market during the forecast period.
The PD-1 inhibitors segment is projected to dominate the market owing to the increased volume of research activities, approvals, and increase in prescriptions of these drugs such as nivolumab and pembrolizumab. Furthermore, the rising adoption of pembrolizumab (KEYTRUDA), due to its proven efficiency to treat multiple FDA-Approved indications like melanoma, non–small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), has also positively influenced the segment growth.
Additionally, the PD-L1 inhibitor segment is anticipated to witness the fastest CAGR during the forecast period owing to a sharp rise in the adoption of durvalumab (IMFINZI), avelumab (BAVENCIO), and others in the segment. Huge investments by the key players in the development of these products are further anticipated to fuel the segment growth over the forecast period.
Key players in the PD1 Resistant Head and Neck Cancer Market are Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.
Some Recent Developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1.54 Billion |
| Market Value in 2033 | USD 5 Billion |
| Growth Rate | CAGR of 12.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Russia, Italy, India, China, Japan, South Korea, Saudi Arabia, Australia, UAE, South Africa, Israel |
| Key Companies Profiled | Advaxis, Inc.; Amgen, Inc.; AstraZeneca Plc; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cel-Sci Corporation; GlaxoSmithKline plc; Incyte Corporation; Merck KGaA; Novartis AG |
| Customization | Available Upon Request |
FMI projects the global PD1 Resistant Head and Neck Cancer Market to expand at a 12.5% value CAGR by 2033.
The global PD1 Resistant Head and Neck Cancer Market are expected to garner a market value of USD 5 billion by 2033.
FMI has projected North America to be one of the most profitable regions for the PD1 Resistant Head and Neck Cancer Market.
APAC region is expected to grow fastest during the forecast period.
Explore Similar Insights
PD1 Resistant Head and Neck Cancer Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
